News Focus
News Focus
icon url

DewDiligence

02/02/16 11:09 AM

#199479 RE: DewDiligence #199478

AXON -28% on PFE’s discontinuing PF-05212377 in AD for lack of efficacy. AXON’s RVT-101 is from the same drug class.
icon url

masterlongevity

02/03/16 7:04 PM

#199526 RE: DewDiligence #199478

$pfe since Tafamidis trade name Vyndaqel) is not listed in their sales breakdkdowns, is it safe to assume they are selling <$50M per quarter.?